Please login to the form below
allogenic cell therapies
This page shows the latest allogenic cell therapies news and features for those working in and with pharma, biotech and healthcare.
Roche bets on T-cell therapies with Adaptimmune deal
Unlike other leaders in next-generation cell therapies, the partners will use allogenic T-cells rather than immune cells taken from and returned to an individual’s body as with many ... their cancer; a significant step towards our goal of making cell
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Pharma deals during February 2014
Cellectis, an expert in allogenic CAR T-cell therapies, signed a strategic collaboration with Servier to cover Cellectic's lead product UCART-19 targeted at leukaemia and lymphomas. ... The FDA Complete Response Letter relating to an advanced renal cell
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
